fda wegovy - Search News

Order byBest matchMost fresh

News

Wegovy, Novo Nordisk and FDA

· 6h · on MSN

The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why.

Continue reading

FDA Approves Wegovy to Treat Serious Liver Disease

BioPharma Dive · 3d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Clinical Advisor1d

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Zacks Investment Research on MSN3d

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...

1d

US FDA greenlights first glucose monitoring system for weight loss

In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results